Source comparison
Mechanism of Action: GHRH Amplification vs Ghrelin Mimicry
CJC-1295 functions as a growth hormone-releasing hormone analog with an extended half-life achieved through Drug Affinity Complex (DAC) technology, which prevents enzymatic degradation by binding to serum albumin. Standard endogenous GHRH has a half-life of fe
This comparison does not assign a generated winner or score.
- CJC-1295 functions as a growth hormone-releasing hormone analog with an extended half-life achieved through Drug Affinity Complex (DAC) technology, which prevents enzymatic degradation by binding to serum albumin. Standard endogenous GHRH has a half-life of fewer than seven minutes; CJC-1295 extends that to approximately eight days, allowing a single subcutaneous injection to amplify multiple natural GH pulses across an entire week. The compound binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating adenylyl cyclase activity and increasing intracellular cAMP—this cascade triggers vesicular exocytosis of pre-stored growth hormone. Because it operates within the hypothalamic-pituitary axis, CJC-1295 remains subject to negative feedback regulation via somatostatin, which means GH release occurs in discrete pulses rather than continuous elevation.
- MK-677 takes a completely different pathway. It's a non-peptide agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by endogenous ghrelin. When administered orally or via injection, MK-677 mimics ghrelin's action by binding to GHS-R1a in both the pituitary and hypothalamus, triggering GH release through a pathway that's independent of GHRH and resistant to somatostatin suppression. A single 25mg oral dose of MK-677 elevates plasma GH levels for 24 hours, with peak concentrations occurring 2–3 hours post-administration and remaining significantly elevated for the duration. This sustained release pattern also drives secondary IGF-1 elevation, which can remain elevated for several days after a single dose—a pharmacokinetic profile that's fundamentally different from the pulsatile action of CJC-1295.
- The clinical implication: if your research model depends on preserving natural circadian GH rhythm—sleep architecture studies, circadian metabolism, or age-related decline in pulsatile secretion—CJC-1295 maintains that physiological structure. If the goal is sustained anabolic signaling, appetite modulation, or maximizing total IGF-1 output independent of pulse timing, MK-677's continuous elevation becomes the mechanistic advantage.